GenesisCare is currently involved in, or leading:
- 26 trials open to recruitment across our network in all 5 states
- 21 in follow up, and
- 12 new studies planned to open over the next 3-6 months
Trials open to recruitment
Trials open to recruitment include those in breast, prostate, melanoma, lung, pancreatic, head and neck and brain.
The group uses its national network to coordinate and share clinical information and know-how, helping inform future approaches to treatment and care.
Dedicated network of research staff
GenesisCare has a dedicated network of research staff across each of its sites and states.
We also have a National Research Manager who is responsible for driving the new studies and working closely with doctors, nurses and radiation therapists to support patients who are actively participating in clinical trials or who are considering taking part.
Our close working relationships with many public and private hospitals across Australia give you access to combined radiation therapy, surgical and/or medical oncology trials.
Our research staff regularly attend national and international meetings related to clinical trial best practice, and they have links with research networks around the world.
Partnership with Trans-Tasman Radiation Oncology Group (TROG)
The Trans-Tasman Radiation Oncology Group (TROG) is a global leader in radiation therapy research.
TROG has worked with over nine hundred researchers and doctors in more than 50 trials involving over 12,000 patient volunteers to help advance cancer treatments.
GenesisCare and TROG work together to improve patient access to clinical trials and promote innovation in research to deliver better patient outcomes.
Currently the GenesisCare network is involved in 7 national radiation therapy trials with TROG with further studies undergoing the rigorous study start up processes. Our current portfolio with TROG includes:
- Enzarad Prostate
- STARS Breast
- P_LUNG Lung
- TOPGEAR Gastro intestinal
- TROG 12.01 HPV Head and Neck
- WBRT Melanoma
- RTN2 Melanoma
Our research program is diverse and the number and type of trials we are involved in is expanding month on month.